Praval Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 15 Year, 7 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.78 M
- Revenue Growth -19.83%
- Profit Growth -46.59%
- Ebitda -10.04%
- Net Worth 7.23%
- Total Assets -0.42%
About Praval Pharmaceuticals
Praval Pharmaceuticals Private Limited (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 February 2010 and has a history of 15 years. Its registered office is in Tiruvallur, Tamil Nadu, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.78 M.
Krishnamurthy Ravisankar and Sivakumar Natarajan serve as directors at the Company.
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74900TN2010PTC074625
- Company No.
074625
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Feb 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Praval Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishnamurthy Ravisankar  | Director | 17-Feb-2010 | Current |
| Sivakumar Natarajan | Director | 04-May-2012 | Current |
Financial Performance of Praval Pharmaceuticals.
Praval Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 19.83% decrease. The company also saw a substantial fall in profitability, with a 46.59% decrease in profit. The company's net worth moved up by a moderate rise of 7.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Praval Pharmaceuticals?
In 2017, Praval Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.78 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.08 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Jun 2019 | Others | ₹0.78 M | Open |
How Many Employees Work at Praval Pharmaceuticals?
Unlock and access historical data on people associated with Praval Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Praval Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Praval Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
